NICE TAs

22/04/2020

TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia

22/04/2020

TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

22/04/2020

TA582: Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)

22/04/2020

TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast

22/04/2020

TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

22/04/2020

TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

22/04/2020

TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer

22/04/2020

TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

21/04/2020

TA533: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence

21/04/2020

TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

21/04/2020

TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer

21/04/2020

TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma

21/04/2020

TA597: Dapagliflozin with insulin for treating type 1 diabetes

21/04/2020

TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer

21/04/2020

TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

21/04/2020

TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

21/04/2020

TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

21/04/2020

TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

21/04/2020

TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line

21/04/2020

TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure